$0.00
+0.00 (+0.00%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BACK is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 0 tracked-famous managers · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Evaluate Umbilical Cord-derived Allogeneic Mesenchymal Stem Cells for the Treatment of BradykinesiaNCT04385056Incidence of Serious Adverse Events and Adverse EventsRandomized · Open-label · Treatment | Phase 1 | Unknown status | Biological: MSCTC-0010 | Bradykinesia | 15 | 2022-07-01 | 2021-01-06 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19